

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/45786 A1

(51) International Patent Classification⁷: A61M 25/01

(74) Agents: CHOW, Y., Ping et al.; Heller Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US).

(21) International Application Number: PCT/US00/34168

(22) International Filing Date:
14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/468,976 21 December 1999 (21.12.1999) US

(71) Applicant: **ADVANCED CARDIOVASCULAR SYSTEMS, INC.** [US/US]; 3200 Lakeside Drive, P.O. Box 58167, Santa Clara, CA 95052-8167 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: **BIAGTAN, Emmanuel, C.**; R-11, 29605 Solana Way, Temecula, CA 92591 (US). **ANDERSON, David, M.**; 43086 Manchester Court, Temecula, CA 92592 (US). **BAJAJ, Shruti**; 41584 Margarita Road #285, Temecula, CA 92591 (US). **CORNISH, Wayne**; 1650 Scooter Lane, Fallbrook, CA 92028 (US). **GOISIENG-FLAO, Brandon**; 32501 Cassino Court, Temecula, CA 92592 (US). **MAHIEU, Ed**; 38748 Calle Sogovin, Hemet, CA 92544 (US). **RICHARDSON, Mark**; 26050 Los Arboles Ranch Road, Escondido, CA 92026 (US).

(54) Title: COMPOSITE GUIDEWIRE INCLUDING AN AXIALLY MOVABLE CORE MEMBER



(57) Abstract: An elongate intracorporeal guiding device for providing access to desired sites within a patients body. The device, which may be configured as a guidewire, is constructed so as to be compatible with sensitive imaging methods such as MRI and the like and not create imaging artifacts or interference with such imaging methods. The guiding device may be constructed so as to have a distal working section that has minimal metallic content or minimal content of materials that can cause imaging artifacts or interference with MRI imaging, other sensitive imaging methods or the like.

WO 01/45786 A1

5

COMPOSITE GUIDEWIRE INCLUDING AN AXIALLY MOVABLE CORE MEMBER

BACKGROUND

This invention relates to the field of guidewires for advancing
10 intraluminal devices such as stent delivery catheters, balloon dilatation
catheters, atherectomy catheters and the like within a patient's body,
specifically, within a patient's vasculature.

In a typical percutaneous procedure in a patient's coronary system,
a guiding catheter having a preformed distal tip is percutaneously
15 introduced into a patient's peripheral artery, e.g. femoral, radial or brachial
artery, by means of a conventional Seldinger technique and advanced
therein until the distal tip of the guiding catheter is seated in the ostium of
a desired coronary artery. There are two basic techniques for advancing a
guidewire into the desired location within the patient's coronary anatomy,
20 the first is a preload technique which is used primarily for over-the-wire
(OTW) devices and the bare wire technique which is used primarily for rail
type systems. With the preload technique, a guidewire is positioned within
an inner lumen of an OTW device such as a dilatation catheter or stent
delivery catheter with the distal tip of the guidewire just proximal to the
25 distal tip of the catheter and then both are advanced through the guiding
catheter to the distal end thereof. The guidewire is first advanced out of
the distal end of the guiding catheter into the patient's coronary
vasculature until the distal end of the guidewire crosses the arterial
location where the interventional procedure is to be performed, e.g. a
30 lesion to be dilated or a dilated region where a stent is to be deployed.

The catheter, which is slidably mounted onto the guidewire, is
advanced out of the guiding catheter into the patient's coronary anatomy
over the previously introduced guidewire until the operative portion of the
intravascular device, e.g. the balloon of a dilatation or a stent delivery

5 catheter, is properly positioned across the arterial location. Once the catheter is in position with the operative means located within the desired arterial location, the interventional procedure is performed. The catheter can then be removed from the patient over the guidewire. Usually, the guidewire is left in place for a period of time after the procedure is
10 completed to ensure reaccess to the arterial location if it is necessary. For example, in the event of arterial blockage due to dissected lining collapse, a rapid exchange type perfusion balloon catheter such as described and claimed in U.S. Patent 5,516,336 (McInnes et al), can be advanced over the in-place guidewire so that the balloon can be inflated to open up the
15 arterial passageway and allow blood to perfuse through the distal section of the catheter to a distal location until the dissection is reattached to the arterial wall by natural healing.

With the bare wire technique, the guidewire is first advanced by itself through the guiding catheter until the distal tip of the guidewire
20 extends beyond the arterial location where the procedure is to be performed. Then a rail type catheter, such as described in U.S. Patent No. 5,061,395 (Yock) and the previously discussed McInnes et al. which are incorporated herein by reference, is mounted onto the proximal portion of the guidewire which extends out of the proximal end of the guiding
25 catheter which is outside of the patient. The catheter is advanced over the guidewire, while the position of the guidewire is fixed, until the operative means on the rail type catheter is disposed within the arterial location where the procedure is to be performed. After the procedure the intravascular device may be withdrawn from the patient over the guidewire
30 or the guidewire advanced further within the coronary anatomy for an additional procedure.

5 Conventional guidewires for angioplasty, stent delivery, atherectomy and other vascular procedures usually comprise metallic elongated core member with one or more tapered sections near the distal end thereof and a flexible body such as a metallic helical coil or a tubular body of polymeric material disposed about the distal portion of the core member. A shapable
10 member, which may be the distal extremity of the core member or a separate shaping ribbon which is secured to the distal extremity of the core member, extends through the flexible body and is secured to the distal end of the flexible body by soldering, brazing or welding which forms a rounded distal tip. Torquing means are provided on the proximal end of
15 the core member to rotate, and thereby steer, the guidewire while it is being advanced through a patient's vascular system.

 Further details of guidewires, and devices associated therewith for various interventional procedures can be found in U.S. Patent 4,748,986 (Morrison et al.); U.S. Patent 4,538,622 (Samson et al.); U.S. Patent
20 5,135,503 (Abrams); U.S. Patent 5,341,818 (Abrams et al.); U.S. Patent 5,345,945 (Hodgson, et al.) and U.S. Patent 5,636,641 (Fariabi) which are hereby incorporated herein in their entirety by reference thereto.

 Conventional metallic guidewires using tapered distal core sections as discussed above can be difficult to use with sensitive imaging systems
25 such as MRI and the like because the metal content of the guidewire can create imaging artifacts that obscure the image produced. What has been needed is a guidewire that is compatible for use with sensitive imaging systems and methods such as MRI and the like.

5

SUMMARY

The invention is directed to an intracorporeal guiding device which can be in the form of a guidewire. The device includes an elongate member having a proximal section and a distal section. The distal section is made at least partially of a fiber composite matrix and has at least one segment with increasing flexibility in a distal direction. The fiber composite matrix can be configured to have little or no metal content so as to avoid creating imaging artifacts with sensitive imaging systems such as MRI and the like. In one embodiment, a flexible body is disposed about the distal section of the elongate member. The flexible body can have a variety of configurations, including a helical coil and a polymer layer. In a particular embodiment, the flexible body which consists of a polymer layer can be doped with a radiopaque material in order to improve visualization of the device under fluoroscopic imaging and the like.

In another embodiment, the elongate intracorporeal guiding device can have an elongate core disposed within a core lumen of the elongate member. The elongate core can be fixed or secured within the core lumen, or it may be moveable in an axial direction. Movement of the elongate core within the core lumen of the device may be used to adjust the flexibility of the distal section.

In another embodiment, a shapeable segment can be secured to the distal end of the elongate member with the flexible body disposed at least partially about the shapeable segment. In some embodiments, the shapeable segment is comprised of metal which can be flattened to provide improved shapeability in a specified orientation.

The invention is also directed to a method of making an elongate intracorporeal guiding device. The method includes disposing at least one

5 layer of thin fiber about a mandrel. This can be done by winding, stranding, braiding or any other suitable method. A binding agent is then applied to the fiber material. If necessary, the binding agent can then be cured. Alternatively, a binding agent may be present on a thin fiber prior to disposing the thin fiber on the mandrel.

10 Finally, the invention is directed to a method of advancing an elongate intracorporeal guiding device within a patient's body. The method includes providing an elongate intracorporeal guiding device having a distal section configured so as not to create imaging artifacts when used with MRI
15 imaging. The elongate intracorporeal guiding device is then inserted into the patient's body and advanced within the patient's body under MRI imaging to a desired site. A distal section configured to not create imaging artifacts with MRI imaging, or other sensitive imaging methods, can be a distal section constructed essentially of non-metallic fiber composite matrix
20 optionally including polymer materials having little or not metallic content.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an elevational view in partial section of an intracorporeal
25 guiding device having features of the invention.

FIG. 2 is a transverse cross sectional view of the intracorporeal guiding device of FIG. 1 taken along lines 2-2 in FIG. 1.

FIG. 3 is a transverse cross sectional view of the intracorporeal guiding device of FIG. 1 taken along lines 3-3 in FIG. 1.

30 FIG. 4 is a transverse cross sectional view of the intracorporeal guiding device of FIG. 1 taken along lines 4-4 in FIG. 1.

5 FIG. 5 is an elevational view in partial section of a part of a distal section of an intracorporeal guiding device having features of the invention.

 FIG. 6 is a transverse cross sectional view of the intracorporeal guiding device of FIG. 5 taken along lines 6-6 in FIG. 5.

10 FIG. 7 is an elevational view in partial section of an intracorporeal guiding device having features of the invention.

 FIG. 8 is a transverse cross sectional view of the intracorporeal guiding device of FIG. 7 taken along lines 8-8 in FIG. 7.

 FIG. 9 is a schematic view of thin fibers being braided onto a
15 mandrel.

 FIG. 10 is a schematic view of a thin fiber being wound onto a mandrel.

 FIG. 11 is a schematic view of thin fibers being stranded onto a mandrel.

20 DETAILED DESCRIPTION

 FIG. 1 shows an intracorporeal guiding device 10 having features of the invention. An elongate member 11 made entirely of fiber composite matrix 12 has a proximal section 13, a proximal end 14, a distal section 15
25 and a distal end 16. Optionally, the elongate member 11 can be made partially out of fiber composite matrix 12. An optional core member 17 is disposed within a core lumen 18 of the elongate member 11 and is axially moveable within the core lumen 18 as indicated by arrow 21. The core member 17 has a proximal end 22 and a distal end 23 and may also be
30 secured within the core lumen 18 either by frictional force, an epoxy or other adhesive, or by any other suitable means. An optional shapeable segment 24 having a proximal end 25 and a distal end 26 has an end cap

5 27 disposed at the proximal end 25 of the shapeable segment 24. The end cap 27 is disposed over and 25 secured to the distal end 16 of the elongate member 11. The end cap 27 may be secured to the distal end 16 of the elongate member 11 by a friction fit, adhesive such as an epoxy, or any other suitable method. A flexible body in the form of a helical coil
10 30 having a proximal end 31 and a distal end 32 is disposed about the shapeable segment 24. The distal end 32 of the helical coil 30 is secured to the distal end 26 of the shapeable segment 24 with a body of solder 33 or the like. The proximal end 31 of the helical coil 30 can be similarly secured to the proximal end 25 of the shapeable segment 24.

15 The fiber composite matrix 12 of the elongate member 11 may be formed in a variety of configurations and from a variety of materials. In the embodiment the intracorporeal guiding device 10 of FIG. 1, the fiber composite matrix 12 can be formed from a plurality of non-metallic thin fibers 34 made of carbon fiber braided over a mandrel (not shown) in one
20 or more layers. A cured or hardened binding agent 35 such as an epoxy resin, polyester resin or other suitable material is disposed about the thin fibers 34 to form the fiber composite matrix 12. The binding agent 35 can optionally be doped with a radiopaque material in order to provide radiopacity to the elongate member 11. Materials such as gold, platinum,
25 platinum-iridium, tungsten, barium compounds or bismuth compounds may be used for doping the binding agent 35. In addition, one or more radiopaque thin fibers 34 can be made of the same or similar radiopaque materials discussed above with regard to radiopaque dopants for the binding agent and may be used when forming the fiber composite matrix
30 12 in order to provide radiopacity to the device 10. In addition, a conductor, insulated or uninsulated, or other type of conduit capable of carrying an electric, light, or other type of signal can be substituted or

5 molded into the thin fibers 34. This can be done in order to carry a signal conveying information such as temperature or pressure from the distal end 16 to the proximal end 14 of the elongate member 11. If a fiber optic is used, light or a light signal can be transmitted from the distal end 16 to the proximal end 14 of the elongate member 11, or from the proximal end 14
10 to the distal end 16. During formation of the elongate member 11, the aforementioned mandrel is removed after the binding agent is cured.

During the formation process for the elongate member 11, the core member 17 could serve as a forming mandrel such as that discussed above, or a separate mandrel could be used for forming the fiber
15 composite matrix 12 and then be removed. A core member 17 could then be inserted into the core lumen 18 once the forming mandrel is removed. The thin fiber 34 could also be wound or stranded about the forming mandrel prior to curing of the binding agent. Any appropriate number of layers of thin fiber 34 may be braided, stranded or wound about a forming
20 mandrel in order to achieve a desired thickness of the fiber composite matrix 12. For an intracorporeal guiding member 10 having a elongate member 11 with a proximal section 13 having an outer diameter of about 0.008 to about 0.040 inches, approximately 1 to about 10 layers of thin fiber 34 may be used, specifically, about 2 to about 6 layers of thin fiber.
25 The thin fibers 34 can have a transverse dimension of about 0.0005 to about 0.002 inch, specifically about 0.001 to about 0.0015 inch and can be made of carbon fiber. Other materials that can be used for the thin fibers 34 may include Nylon, Kevlar, fiberglass and the like.

The flexibility of the elongate member 11 can be controlled to some
30 degree by varying the manner in which the one or more thin fibers are configured within the fiber composite matrix with respect to axial position along the elongate member 11. Specifically, the angle the thin fiber 34

5 makes with a line parallel to a longitudinal axis 36 of the elongate member 12 adjacent the thin fiber 34 can affect the longitudinal flexibility of the elongate member and hence the intracorporeal guiding device 10. In addition, the distal section 15 of the elongate member 11 can be tapered to a reduced outer transverse dimension distally in one or more segments
10 in order to increase the flexibility of such a segment. The tapering of a segment can be achieved by grinding a segment of substantially constant outer diameter after formation of the elongate member 11. Alternatively, the tapering of a segment could be achieved by varying the number of layers or configuration of the thin fiber or fibers 34 in the formation process
15 of the elongate member 11. Also, the diameter of the core lumen 18 within the elongate member 11 could be increased distally in a segment of the distal section 15 of the elongate member 11 in order to increase the flexibility of the segment.

The core member 17 can be made from a metal such as stainless
20 steel, MP35N, L605 or other high strength materials. The core member 17 may also be configured to be radiopaque and can have materials such as gold, platinum, platinum-iridium, tungsten and the like contained therein. The core member 17 may also be made of a fiber composite material similar to that of the elongate member 11 with a binding agent for such a
25 fiber composite material being doped with a non-metallic radiopaque material in order to provide radiopacity to the core member 17 and avoid introduction of metallic content which might interfere with sensitive imaging methods as discussed above. The core member 17 can have an outer transverse dimension of about 0.001 to about 0.015 inches, specifically
30 about 0.002 to about 0.005 inches. The core member 17 can also be ground to have one or more tapered segments, specifically, tapered segment tapering distally to a reduced transverse dimension in order to

- 5 provide greater flexibility in the distal section 15 of the elongate member 11.

Generally, the shapeable segment 24 can have a configuration similar to shapeable segments of guiding devices known in the art. Regarding the embodiment of the guiding device 10 shown in FIG. 1, the
10 shapeable segment 24 is formed of stainless steel which has optionally been flattened. Specifically, the shapeable segment 24 has been flattened to a progressively greater degree in a distal direction. Thus, a thickness of the flattened portion at the proximal end 25 of the shapeable segment 24 is thicker than the thickness of the flattened portion of the shapeable
15 segment 24 at the distal end 26 of the shapeable segment 24. The length of the flexible segment 24 can be from about 2 to about 30 cm, specifically, about 3 to about 10 cm. The thickness of the shapeable segment 24 at the flattened distal end can be from about 0.0005 to about 0.006 inch, specifically, about 0.001 to about 0.002 inch. Other materials
20 suitable for the shapeable segment 24 include MP35N, L605 or other high strength materials.

The helical coil 30 can be made from a variety of suitable materials including stainless steel, platinum, platinum iridium, gold or the like. The helical coil 30 could also be made from a fiber composite matrix or other
25 non-metal material in order to enable the intracorporeal guiding device 10 to have a distal section or an overall composition with a zero or minimum amount of metallic composition. As mentioned above, for certain applications and uses, minimizing the metallic content of the intracorporeal guiding device 10 improves compatibility with sensitive imaging devices
30 such as MRI. The material of the helical coil 30 can have a transverse dimension of about 0.001 to about 0.005 inch, specifically, about 0.002 to about 0.003 inch.

5 The nominal outer transverse dimension of the proximal section 13 of the elongate member 11 can be from about 0.005 to about 0.035, specifically, about 0.01 to about 0.02, and more specifically about 0.012 to about 0.016 inch. The overall length of the intracorporeal guiding device 10 can be from about 100 to about 300 cm, specifically about 150 to about
10 200 cm.

 FIG. 2 is a transverse cross sectional view of the intracorporeal guiding device 10 of FIG. 1 taken along lines 2-2 in FIG. 1. The fiber composite matrix 12 is substantially concentrically disposed about the core member 17 as discussed above. In FIG. 3, the end cap 27 is disposed
15 about the fiber composite matrix 12 which is substantially concentrically disposed about the core lumen 18. In FIG. 4, the helical coil 30 is disposed about the shapeable segment 24.

 FIGS. 5 and 6 depict an alternative embodiment of a shapeable segment 40 wherein the end cap 27 of the shapeable segment 24 of FIG. 1 has been replaced with a handle portion 41 which is disposed within and
20 secured to the distal end 42 of the elongate member 43. A configuration such as that shown in FIG. 5 allows for a smooth continuous transition from an outer surface 44 of the elongate member 43 to an outer surface 45 of the helical coil 46. A fiber composite matrix 47 is substantially
25 concentrically disposed about the handle portion 41 of the shapeable segment 40. Components of the embodiment of the intracorporeal guiding device 48 shown in FIGS. 5 and 6 could have similar relationships, dimensions and materials to similar components of the embodiment of the intracorporeal guiding device 10 shown in FIGS. 1-4.

30 FIGS. 7 and 8 show another embodiment of an intracorporeal guiding device 50 having features of the invention. An elongate member 51 has a proximal section 52, a proximal end 53, a distal section 54 and a

5 distal end 55. The distal section 54 has a tapered segment 56 which
tapers distally to a reduced transverse dimension in order to increase the
flexibility of the distal section 54. The elongate member 51 is formed of a
fiber composite matrix 57 such as that described above with regard to
other embodiments of the invention. A core member 58 is optionally
10 secured within a core lumen 61 of the elongate member 51. The core
member 58 can be made of a non-metallic fiber composite matrix or other
essentially non-metallic material in order to avoid interference with
sensitive imaging systems such as MRI and the like. The tapered
segment 56 of the distal section 54 of the elongate member 51 tapers in a
15 curved configuration which can provide a smooth transition in flexibility. A
flexible body in the form of a polymer layer 62 is substantially
concentrically disposed about the distal section 54 of the elongate
member 51. A rounded polymer cap 63 is secured to the distal end 55 of
the elongate member 51 to facilitate securement of the polymer layer 62 to
20 the elongate member 51 and to provide a rounded non-traumatic tip for
the intracorporeal guiding device 50. The rounded polymer cap 63 can be
a separate element as shown in FIG. 7, or it may be a continuation and
integral portion of polymer layer 62. The polymer layer 62 has a proximal
end 63 and distal end 64.

25 The polymer layer 62 can be made from a diverse range of
materials, including polyurethane, polyethylene, Nylon, silicone, or any
other suitable polymer. The polymer layer 62 can optionally be doped with
a radiopaque material in order to facilitate imaging of the guiding device 50
under fluoroscopy. The polymer layer 62 can be applied by coextrusion,
30 heat shrink, bonding with a suitable adhesive or any other appropriate
method. The polymer layer 62 can be formed on the distal section 54 of
the elongate member 51 or may be extruded independently and later

5 secured to the distal section 54. The length and outer dimensions of the
polymer layer 62 can be similar to those of the helical coil 30 discussed
above. FIG. 8 is a transverse cross sectional view of the intracorporeal
guiding device 50 of FIG. 7 taken along lines 8-8 in FIG. 7. The polymer
layer 62 is shown substantially concentrically disposed about the fiber
10 composite matrix 57 which is substantially concentrically disposed about
the core member 58. Components of the embodiment of the
intracorporeal guiding device 50 shown in FIGS. 7 and 8 could have
similar relationships, dimensions and materials to similar components of
the embodiment of the intracorporeal guiding device 10 shown in FIGS. 1-
15 6.

FIG. 9 illustrates four thin fibers 70 being braided onto a mandrel.
FIG. 10 illustrates a single thin fiber 72 being wound onto a mandrel 73. A
double layer section 74 is shown where the thin fiber 72 been wound back
onto itself in order to form two layers. FIG. 11 shows four thin fibers 75
20 being stranded onto a mandrel 76. Also shown is the pitch angle 77 that a
line 78 extending from one of the thin fibers 75 makes with a line 79
orthogonal to a longitudinal axis 80 of the mandrel 76. The pitch angle 77
of stranded, braided or wound thin fiber 75 can vary significantly. The
pitch angle 77 can be just over zero degrees for a single thin fiber 75
25 being wound close spaced so that adjacent windings are touching each
other. The pitch angle 77 can be up to 90 degrees for multiple stranded
thin fibers 75 which extend essentially parallel to the longitudinal axis 80 of
the mandrel 76. In one embodiment, the pitch angle 77 can be from about
20 to about 70 degrees, specifically, about 30 to about 60 degrees, and
30 more specifically about 40 to about 50 degrees. Such variations in pitch
angle 77 can be used to control the flexibility of the resulting elongate
member for a fixed cross section of fiber composite material.

5 While particular forms of the invention have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

5

WHAT IS CLAIMED IS:

1. An intracorporeal guiding device comprising an elongate
10 member having a proximal section and a distal section made at least
partially of a fiber composite matrix and having at least one segment with
increasing flexibility in a distal direction.
2. The intracorporeal guiding device of claim 1 wherein the fiber
composite matrix is comprised of a material selected from the group
15 consisting of carbon fiber, fiberglass, Nylon and Kevlar.
3. The intracorporeal guiding device of claim 1 further
comprising a flexible body disposed about the distal section of the
elongate member.
4. The elongate intracorporeal guiding member of claim 3
20 wherein the flexible body is comprised of a helical coil.
5. The elongate intracorporeal guiding device of claim 3 wherein
the flexible body is comprised of a polymer layer.
6. The elongate intracorporeal guiding device of claim 5 wherein
the polymer layer is doped with a radiopaque material.
- 25 7. The elongate intracorporeal guiding device of claim 4 wherein
the helical coil is made of a non-metal fiber composite matrix.
8. The elongate intracorporeal guiding device of claim 7 wherein
the non-metal fiber composite matrix of the helical coil is doped with a
radiopaque material.
- 30 9. The elongate intracorporeal guiding device of claim 1 further
comprising an elongate core disposed within a core lumen of the elongate
member.

5 10. The elongate intracorporeal guiding device of claim 9 wherein the core member is comprised of metal.

 11. The elongate intracorporeal guiding device of claim 10 wherein the core member is radiopaque.

 12. The elongate intracorporeal guiding device of claim 9 wherein
10 the core member is comprised of a fiber composite matrix.

 13. The elongate intracorporeal guiding device of claim 9 wherein the core member is axially moveable within a lumen of the elongate member.

 14. The elongate intracorporeal guiding device of claim 1 wherein
15 the composite fiber matrix comprises at least one thin fiber in a stranded configuration.

 15. The elongate intracorporeal guiding device of claim 1 wherein the composite fiber matrix comprises at least one thin fiber in a wound configuration.

20 16. The elongate intracorporeal guiding device of claim 1 wherein the composite fiber matrix comprises at least one layer of thin fibers in a braided configuration.

 18. The elongate intracorporeal guiding device of claim 17 wherein the shapeable segment further comprises an end cap configured
25 to be disposed over and secured to the distal end of the elongate member.

 19. The elongate intracorporeal guiding device of claim 17 wherein the shapeable segment further comprises a handle portion configured to be disposed within and secured to the distal end of the elongate member.

30 20. The elongate intracorporeal guiding device of claim 17 wherein the shapeable member is comprised of metal.

5 21. A method of making an elongate intracorporeal guiding device comprising:

 disposing at least one layer of thin fiber material about a mandrel;

 applying a binding agent to the fiber material.

10 22. The method of claim 21 further comprising curing the binding material after it has been applied to the fiber material.

 23. The method of claim 21 further comprising removing the mandrel after the binding material has been applied.

 24. The method of claim 21 wherein the thin fiber material is applied by winding the material about the mandrel.

 25. The method of claim 21 wherein the thin fiber material is applied by stranding the material about the mandrel.

 26. The method of claim 21 wherein the thin fiber material is applied by braiding the material about the mandrel.

20 27. A method of making an elongate intracorporeal guiding device comprising disposing at least one layer of thin fiber material having a binding agent disposed thereon about a mandrel and curing the binding agent.

 28. A method of advancing an elongate intracorporeal guiding device within a patient's body comprising:

 a) providing an elongate intracorporeal guiding device having a distal section configured so as not to create imaging artifacts when used with MRI imaging

 b) inserting the guiding device into the patient's body

30 c) advancing the guiding device within the patient's body under MRI imaging to a desired site.

1/4





FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34168

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M25/01

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 820 782 A (TARGET THERAPEUTICS INC) 28 January 1998 (1998-01-28)	1-5, 14-16, 21-27
Y	column 4, line 50 -column 5, line 47 column 12, line 7 - line 39; figures 1,2 column 13, line 12 - line 40 column 19, line 44 - line 46 ---	6,9,10, 13
Y	US 4 657 024 A (CONEYS THOMAS A) 14 April 1987 (1987-04-14) column 3, line 35-45; figures 1-3 ---	6
Y	EP 0 468 645 A (BARD INC C R) 29 January 1992 (1992-01-29) abstract column 4, line 40 -column 5, line 20 -----	9,10,13

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 April 2001

Date of mailing of the international search report

09.05.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gaillard, A

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/34168

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28, 17-20
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☒ Claims Nos.: 18-20, 28
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18-20,28

No search report was established in respect of claims 18-20, because claim 17 is missing in the file and claims 18-20 are dependent claims of claim 17.

No search report was established in respect of claim 28 under article 17(2) PCT, because it relates to a excluded matter (defining a therapeutic method) under rule 39.1(iv).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/34168

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0820782	A	28-01-1998	US 5827201 A	27-10-1998
			AU 694964 B	06-08-1998
			AU 2876597 A	05-02-1998
			CA 2210641 A	26-01-1998
			JP 2992251 B	20-12-1999
			JP 10066727 A	10-03-1998
			NO 973427 A	27-01-1998

US 4657024	A	14-04-1987	EP 0033659 A	12-08-1981
			JP 56119263 A	18-09-1981

EP 0468645	A	29-01-1992	US 5040543 A	20-08-1991
			IE 912606 A	29-01-1992
			JP 4236965 A	25-08-1992
